ABCAM Plc Director/PDMR Shareholding (8858S)
March 22 2016 - 5:33AM
UK Regulatory
TIDMABC
RNS Number : 8858S
ABCAM Plc
22 March 2016
For immediate release 22 March 2016
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR Shareholding: LTIP
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools, announces that on 21 March
2016, the PDMR listed below was granted a share award in the form
of Nil Cost Options under the Abcam plc Long-Term Incentive Plan
("LTIP"):
Name Number of 0.2 pence Ordinary
Shares subject to the LTIP
Award
Suzanne Smith 17,241
The Awards will vest in three years' time subject to continued
employment and subject to the satisfaction of performance
conditions based on earnings per share growth and meeting strategic
KPIs.
For further information, please contact:
+ 44 (0) 1223
Abcam 696 000
Suzanne Smith, Company Secretary
J.P.Morgan Cazenove - Nominated + 44 (0) 20
Adviser & Corporate Broker 7742 4000
James Mitford / Alex Bruce - Nominated
Adviser
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's ten offices are located in the world's leading life
science research hubs, enabling local services and multi-language
support. Founded in 1998 and headquartered in Cambridge, UK, the
Company sells to more than 100 countries. Abcam was admitted to AIM
in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSKLLBLQXFXBBB
(END) Dow Jones Newswires
March 22, 2016 05:33 ET (09:33 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024